NGNE
NGNE
NASDAQ · Biotechnology

Neurogene Inc

$28.56
+0.25 (+0.88%)
As of Sep 28, 2:31 PM ET ·
Financial Highlights (FY 2026)
Revenue
808.7K
Net Income
-65,643,442
Gross Margin
—
Profit Margin
-8,123.7%
Rev Growth
—
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — 29.2% 29.2% 29.2%
Operating Margin -8,930.3% 18.5% 15.2% 14.8%
Profit Margin -8,123.7% 13.1% 12.4% 15.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 808.7K 64.19M 65.56M 69.77M
Gross Profit — 18.73M 19.14M 20.36M
Operating Income -72,221,415 11.89M 9.99M 10.31M
Net Income -65,643,442 8.40M 8.13M 10.74M
Gross Margin — 29.2% 29.2% 29.2%
Operating Margin -8,930.3% 18.5% 15.2% 14.8%
Profit Margin -8,123.7% 13.1% 12.4% 15.4%
Rev Growth — +4.7% +24.1% +24.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 44.6K 117.21M 111.57M 122.33M
Total Equity 148.58M 131.11M 140.60M 129.06M
D/E Ratio 0.00 0.89 0.79 0.95
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -70,237,992 15.55M 13.35M 15.74M
Free Cash Flow — 10.13M 9.92M 11.85M